Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: BENEFIT-KOREA (BEnefits after 24 weeks of NEbivolol administration For essential hypertensIon patients wiTh various comorbidities and treatment environments in Korea) study, an observational study in South Korea, demonstrated the efficacy and safety of nebivolol in Asian patients with essential hypertension with and without comorbidities in real-world settings. We present a subanalysis of the efficacy and safety of nebivolol across age and sex in the BENEFIT-KOREA cohort. Methods: Adult South Korean patients with essential hypertension participated in the prospective, single-arm, open, observational BENEFIT-KOREA study; 3011 patients received nebivolol as monotherapy or add-on therapy. Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), and pulse rate at 12 and 24 weeks were evaluated. Participants were divided into three age groups—young males and females: < 50 years; middleaged males and females: ≥50 years to < 70 years; and older males and females: ≥70 years. Results: The mean age of study participants was 63.5 ± 12.9 years; majority were between 50 and 69 years of age and 40.4% were females. A significant decrease was observed in mean SBP, DBP, and pulse rate from baseline at 12 and 24 weeks in males and females across all age groups analyzed (all P < 0.001 vs. baseline), with no significant difference in mean reduction in SBP and DBP from baseline between sex within the age groups. Majority of reported adverse events were mild. The incidence of adverse events was lower in young participants versus middleaged and older participants. Conclusions: Our subanalysis from the real-world BENEFIT-KOREA study in Asian patients with essential hypertension demonstrated the efficacy and safety of once-daily nebivolol across age groups with no between-sex differences. Trial registration: Name of the registry: clinicaltrials.gov. Trial registration number: NCT03847350. Date of registration: February 20, 2019 retrospectively registered.
Abstract
Background: BENEFIT-KOREA (BEnefits after 24 weeks of NEbivolol administration For essential hypertensIon patients wiTh various comorbidities and treatment environments in Korea) study, an observational study in South Korea, demonstrated the efficacy and safety of nebivolol in Asian patients with essential hypertension with and without comorbidities in real-world settings. We present a subanalysis of the efficacy and safety of nebivolol across age and sex in the BENEFIT-KOREA cohort. Methods: Adult South Korean patients with essential hypertension participated in the prospective, single-arm, open, observational BENEFIT-KOREA study; 3011 patients received nebivolol as monotherapy or add-on therapy. Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), and pulse rate at 12 and 24 weeks were evaluated. Participants were divided into three age groups—young males and females: < 50 years; middleaged males and females: ≥50 years to < 70 years; and older males and females: ≥70 years. Results: The mean age of study participants was 63.5 ± 12.9 years; majority were between 50 and 69 years of age and 40.4% were females. A significant decrease was observed in mean SBP, DBP, and pulse rate from baseline at 12 and 24 weeks in males and females across all age groups analyzed (all P < 0.001 vs. baseline), with no significant difference in mean reduction in SBP and DBP from baseline between sex within the age groups. Majority of reported adverse events were mild. The incidence of adverse events was lower in young participants versus middleaged and older participants. Conclusions: Our subanalysis from the real-world BENEFIT-KOREA study in Asian patients with essential hypertension demonstrated the efficacy and safety of once-daily nebivolol across age groups with no between-sex differences. Trial registration: Name of the registry: clinicaltrials.gov. Trial registration number: NCT03847350. Date of registration: February 20, 2019 retrospectively registered.
참고문헌 (29)
- Vögele A, "Effectiveness and safety of beta blockers in the management of hypertension in older adults : a systematic review to help reduce inappropriate prescribing", BMC Geriatr, 17, pp.224~ (2017)
- Forouzanfar MH, "Global burden of hypertension and systolic blood pressure of at least 110 to 115mm hg, 1990-2015", JAMA, 317, pp.165~182 (2017)
- Choi HM, "Sex differences in hypertension prevalence and control : analysis of the 2010-2014 Korea National Health and nutrition examination survey", PLoS One, 12, pp.e0178334~ (2017)
- Gillis EE, "Sex differences in hypertension : recent advances", Hypertension, 68, pp.1322~1327 (2016)
- Williams B, "2018 practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology : ESH", ESC task force for the Management of Arterial Hypertension, 2018, pp.36, 2284~2309
- Chow CK, "Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries", JAMA, 310, pp.959~968 (2013)
- 김현창, "Gender Differences in Hypertension Control Among Older Korean Adults: Korean Social Life, Health, and Aging Project", 예방의학회지, 48(1), pp.38~47 (2015), 대한예방의학회
- Gudmundsdottir H, "Hypertension in women : latest findings and clinical implications", Ther Adv Chronic Dis, 3, pp.137~146 (2012)
- Hage FG, "Hypertension in women", Kidney Int Suppl, 3, pp.352~356 (2013)
- Muiesan ML, "Gender differences in antihypertensive treatment : myths or legends", High Blood Press Cardiovasc Prev, 23, pp.105~113 (2016)
- Benjamin EJ, "Heart disease and stroke statistics-2018 update : a report from the American Heart Association", Circulation, 137, pp.e67~492 (2018)
- Ishag Adam, "Red cell distribution width and preeclampsia: a systematic review and meta-analysis", Clinical Hypertension, 25(4), pp.16~23 (2019), 대한고혈압학회[DOI]
- Everett B, "Gender differences in hypertension and hypertension awareness among young adults", Biodemography Soc Biol, 61, pp.1~17 (2015)
- Mancia G, "The autonomic nervous system and hypertension", Circ Res, 114, pp.1804~1814 (2014)
- Baker SE, "Aging alters the relative contributions of the sympathetic and parasympathetic nervous system to blood pressure control in women", Hypertension, 72, pp.1236~1242 (2018)
- Olawi N, "Nebivolol in the treatment of arterial hypertension", Basic Clin Pharmacol Toxicol, 125, pp.189~201 (2019)
- Shin J, "Real-world efficacy and safety of nebivolol in Korean patients with hypertension from the BENEFIT KOREA study", J Hypertens, 38, pp.527~535 (2020)
- Hae-Young Lee, "2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension", Clinical Hypertension, 25(4), pp.51~74 (2019), 대한고혈압학회[DOI]
- Flather MD, "SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)", Eur Heart J., 26, pp.215~225 (2005)
- Thomopoulos C, "Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality : 14-effects of different classes of antihypertensive drugs in older and younger patients : overview and meta-analysis", J Hypertens, 36, pp.1637~1647 (2018)
- Kallistratos MS, "Vasodilator β-blockers : a different class of antihypertensive agents", Futur Cardiol, 10, pp.669~671 (2014)
- Van Bortel LM, "Efficacy and tolerability of nebivolol compared with other antihypertensive drugs : a meta-analysis", Am J Cardiovasc Drugs, 8, pp.35~44 (2008)
- Germino FW, "Efficacy and tolerability of nebivolol : does age matter? A retrospective analysis of three randomized, placebocontrolled trials in stage I-II hypertension", Ther Adv Cardiovasc Dis, 6, pp.185~199 (2012)
- Ladage D, "Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age", J Cardiovasc Pharmacol, 56, pp.275~281 (2010)
- Del Colle S, "Antihypertensive drugs and the sympathetic nervous system", J Cardiovasc Pharmacol, 50, pp.487~496 (2007)
- Chiladakis JA, "Autonomic effects of nebivolol versus atenolol in healthy subjects", Cardiovasc Drugs Ther, 18, pp.469~473 (2004)
- Maffei A, "Characterization of nitric oxide release by nebivolol and its metabolites", Am J Hypertens, 19, pp.579~586 (2006)
- Denic A, "Structural and functional changes with the aging kidney", Adv Chronic Kidney Dis, 23, pp.19~28 (2016)
- Glassock RJ, "The implications of anatomical and functional changes of the aging kidney : with an emphasis on the glomeruli", Kidney Int, 82, pp.270~277 (2012)